These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 21348320

  • 1. [Unsatisfactory results of upstream therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the prevention of recurrent atrial fibrillation].
    Disertori M, Zeni P, Quintarelli S, Bonmassari R.
    G Ital Cardiol (Rome); 2010 Nov; 11(11):829-34. PubMed ID: 21348320
    [Abstract] [Full Text] [Related]

  • 2. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
    Savelieva I, Kakouros N, Kourliouros A, Camm AJ.
    Europace; 2011 Mar; 13(3):308-28. PubMed ID: 21345926
    [Abstract] [Full Text] [Related]

  • 3. [Upstream therapy of atrial fibrillation in patients with heart failure].
    Alboni P, Gianfranchi L, Pacchioni F.
    G Ital Cardiol (Rome); 2009 Sep; 10(9):566-71. PubMed ID: 19891248
    [Abstract] [Full Text] [Related]

  • 4. Focus on renin-angiotensin system modulation and atrial fibrillation control after GISSI AF results.
    Durin O, Pedrinazzi C, Inama G.
    J Cardiovasc Med (Hagerstown); 2010 Dec; 11(12):912-8. PubMed ID: 20729747
    [Abstract] [Full Text] [Related]

  • 5. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
    Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G, GISSI-AF Investigators.
    J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
    [Abstract] [Full Text] [Related]

  • 6. Reviewing the future of renin-angiotensin system blockade: the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation.
    Ducharme A, Schiffrin EL.
    Can J Cardiol; 2010 Dec; 26 Suppl E():21E-23E. PubMed ID: 21620287
    [Abstract] [Full Text] [Related]

  • 7. Therapy with renin-angiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: who is a responder?
    Berkowitsch A, Neumann T, Kuniss M, Janin S, Wojcik M, Zaltsberg S, Mitrovic V, Pitschner HF.
    Pacing Clin Electrophysiol; 2010 Sep; 33(9):1101-11. PubMed ID: 20487340
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
    Zhang Y, Zhang P, Mu Y, Gao M, Wang JR, Wang Y, Su LQ, Hou YL.
    Clin Pharmacol Ther; 2010 Oct; 88(4):521-31. PubMed ID: 20811347
    [Abstract] [Full Text] [Related]

  • 10. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B, Derntl M, Marx M, Lercher P, Gössinger HD.
    Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
    [Abstract] [Full Text] [Related]

  • 11. Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart.
    Fazio G, Pizzuto C, Sutera L, Guttilla D, Di Gesaro G, Cascio C, Novo G, Assennato P, Novo S.
    Minerva Cardioangiol; 2007 Jun; 55(3):311-5. PubMed ID: 17534249
    [Abstract] [Full Text] [Related]

  • 12. [Non-antiarrhythmic drug therapy for the prevention of atrial fibrillation?].
    Fauchier L, Zannad N, Clementy N, Pierre B, Cosnay P, Babuty D.
    Ann Cardiol Angeiol (Paris); 2010 Dec; 59 Suppl 1():S28-32. PubMed ID: 21211623
    [Abstract] [Full Text] [Related]

  • 13. Impact of angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation.
    Tayebjee MH, Creta A, Moder S, Hunter RJ, Earley MJ, Dhinoja MB, Schilling RJ.
    Europace; 2010 Nov; 12(11):1537-42. PubMed ID: 20682557
    [Abstract] [Full Text] [Related]

  • 14. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.
    Anand K, Mooss AN, Hee TT, Mohiuddin SM.
    Am Heart J; 2006 Aug; 152(2):217-22. PubMed ID: 16875900
    [Abstract] [Full Text] [Related]

  • 18. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis.
    Huang G, Xu JB, Liu JX, He Y, Nie XL, Li Q, Hu YM, Zhao SQ, Wang M, Zhang WY, Liu XR, Wu T, Arkin A, Zhang TJ.
    Eur J Clin Invest; 2011 Jul; 41(7):719-33. PubMed ID: 21250983
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the renin-angiotensin system for prevention of atrial fibrillation.
    Zografos T, Katritsis DG.
    Pacing Clin Electrophysiol; 2010 Oct; 33(10):1270-85. PubMed ID: 20636314
    [Abstract] [Full Text] [Related]

  • 20. Upstream therapy of atrial fibrillation.
    Smit MD, Van Gelder IC.
    Expert Rev Cardiovasc Ther; 2009 Jul; 7(7):763-78. PubMed ID: 19589113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.